Cohen Joel L, Cohen Goldie, Solish Nowell, Murray Christian A
AboutSkin Dermatology and DermSurgery, Englewood, CO 80113, USA.
Facial Plast Surg Clin North Am. 2007 Feb;15(1):17-30, v-vi. doi: 10.1016/j.fsc.2006.10.002.
Idiopathic localized hyperhidrosis, called for hyperhidrosis, affects almost 3% of the US population. The most frequent anatomic sites of involvement include the axillae, palms, soles, and face. For those affected, this condition can be extremely socially debilitating and interfere with work activities. Until recently, frequently ineffective topical regimens or problematic surgical procedures have been the treatments of choice. Since 1996, intracutaneous injections of botulinum toxin have been used as a minimally invasive treatment for this condition with numerous studies documenting safety, efficacy, and extremely high levels of patient satisfaction. Botulinum toxin type A (Botox) was approved by the US Food and Drug Administration in 2004 for the treatment of axillary hyperhidrosis.
特发性局部多汗症，简称多汗症，影响着近3%的美国人口。最常受累的解剖部位包括腋窝、手掌、脚底和面部。对于患者来说，这种情况会极大地影响社交能力，并干扰工作。直到最近，常用的局部治疗方案往往效果不佳，而手术治疗又存在问题，因此这些一直是首选的治疗方法。自1996年以来，皮内注射肉毒杆菌毒素已被用作这种疾病的微创治疗方法，大量研究证明了其安全性、有效性以及极高的患者满意度。A型肉毒杆菌毒素（保妥适）于2004年被美国食品药品监督管理局批准用于治疗腋窝多汗症。
